Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA
Jonathan Schultz, Mary K. McCarthy, Cody Rester, Katherine R. Sabourin, Kyle Annen, Melkon DomBourian, Elan Eisenmesser, Ashley Frazer‐Abel, Vijaya Knight, Thomas Jaenisch, Thomas E. Morrison, Rosemary Rochford, Ross M. Kedl
Abstract
Serological testing of large representative populations for antibodies to SARS-CoV-2 is needed to estimate seroprevalence, transmission dynamics, and the duration of antibody responses from natural infection and vaccination. In this study, a high-throughput SARS-CoV-2 multiplex microsphere immunoassay (MMIA) was developed for the receptor binding domain (RBD) and nucleocapsid (N) that was more sensitive than enzyme-linked immunosorbent assay (ELISA) (98% versus 87%).
Topics & Concepts
MultiplexSeroprevalenceImmunoassayDried bloodMicrosphereSpotsVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Dried blood spotCoronavirus disease 2019 (COVID-19)BiologySerologyMedicineChromatographyAntibodyImmunologyChemistryPathologyGeneticsInfectious disease (medical specialty)EngineeringDiseaseChemical engineeringSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingBiosensors and Analytical Detection